We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Marina Biotech Reports Interim Results of Their Phase 2-Enabling Toxicology Study for CEQ508

News   Feb 25, 2011

 
Marina Biotech Reports Interim Results of Their Phase 2-Enabling Toxicology Study for CEQ508
 
 
Advertisement
 

RELATED ARTICLES

UK Government-Funded COVID-19 Vaccine Phase 1/2 Trials Report Positive Data

News

A new COVID-19 vaccine candidate – VLA2001 – developed by Valneva has shown positive results in a UK Government-funded Phase I/II clinical trial, according to a press release.

READ MORE

A Long-Acting Injectable Therapy To Treat COVID-19

News

University of Liverpool researchers have demonstrated the potential of repurposing an existing drug called niclosamide into a long-acting injectable therapy that could be used to treat COVID-19.

READ MORE

Delivering Chemotherapy to the Brain Using Ion Pumps

News

The majority of patients experience a recurrence of malignant brain tumors despite surgery and subsequent treatment with chemotherapy and radiation. Researchers have shown that an ion pump can deliver drugs more accurately in cells in culture, which gives less severe adverse effects in chemotherapy.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE